In light of the approval of the first gene therapy for sickle cell disease, the Principal Investigator of our program Sjaak Philipsen was interviewed by NRC. In the interview he explains how sickle cell disease works, why this approval is groundbreaking for the field of medicine, and also why more research still is needed. To make the therapies available and accessible for all, other methods need to be developed too. That will lower the price for the incredibly expensive therapies, and will make the research more robust and safe.
If you have a subscription to NRC, you can read the interview here!
Picture by F. Gilbert/AP: Microscopic image of sickle-shaped red blood cells in a patient with sickle cell disease.
Comentários